-+ 0.00%
-+ 0.00%
-+ 0.00%

12 Health Care Stocks Moving In Friday's Pre-Market Session

Benzinga·05/09/2025 12:10:06
Listen to the news

Gainers

  • Shuttle Pharmaceuticals (NASDAQ:SHPH) stock increased by 79.5% to $0.48 during Friday's pre-market session. The company's market cap stands at $3.0 million.
  • SCWorx (NASDAQ:WORX) stock increased by 51.0% to $0.83. The market value of their outstanding shares is at $1.9 million.
  • Corvus Pharma (NASDAQ:CRVS) stock increased by 29.85% to $4.35. The company's market cap stands at $296.5 million. As per the press release, Q1 earnings came out yesterday.
  • CytomX Therapeutics (NASDAQ:CTMX) shares increased by 24.77% to $1.36. The company's market cap stands at $108.9 million.
  • Generation Bio (NASDAQ:GBIO) shares increased by 18.62% to $0.43. The company's market cap stands at $28.6 million. As per the press release, Q1 earnings came out 2 days ago.
  • Adicet Bio (NASDAQ:ACET) stock rose 16.82% to $0.56. The company's market cap stands at $46.2 million. The company's, Q1 earnings came out 3 days ago.

Losers

  • Jade Biosciences (NASDAQ:JBIO) shares decreased by 44.5% to $5.0 during Friday's pre-market session. The market value of their outstanding shares is at $263.0 million.
  • Varex Imaging (NASDAQ:VREX) shares declined by 42.2% to $5.0. The company's market cap stands at $206.1 million. As per the press release, Q2 earnings came out yesterday.
  • NuCana (NASDAQ:NCNA) shares decreased by 41.5% to $0.06.
  • Iovance Biotherapeutics (NASDAQ:IOVA) stock decreased by 35.02% to $2.06. The company's market cap stands at $687.9 million. The company's, Q1 earnings came out yesterday.
  • Polyrizon (NASDAQ:PLRZ) shares declined by 30.93% to $0.41. The company's market cap stands at $2.7 million.
  • Protalix BioTherapeutics (AMEX:PLX) stock fell 26.65% to $2.12. The market value of their outstanding shares is at $168.5 million. As per the news, the Q1 earnings report came out today. See Also: www.benzinga.com/money/best-healthcare-stocks/

This article was generated by Benzinga's automated content engine and reviewed by an editor.